{
    "2019-05-02": [
        [
            {
                "time": "2018-04-15",
                "original_text": "Teva's new migraine drug helps to contain profit fall",
                "features": {
                    "keywords": [
                        "Teva",
                        "migraine drug",
                        "profit fall"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-25",
                "original_text": "United Therapeutics (UTHR) Down Despite Q1 Earnings Beat",
                "features": {
                    "keywords": [
                        "United Therapeutics",
                        "Q1 Earnings Beat",
                        "Down"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-13",
                "original_text": "Lilly to Present New Data at AAN 2019 on EmgalityÂ® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Emgality",
                        "Lasmiditan",
                        "AAN 2019",
                        "Headache Disorders Portfolio"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}